BLCO may be sold in 2025 to service the debt of majority shareholder BHC, and any sale will be at a premium to the current stock price. Explore more details here.

Feb 6 (Reuters) - Bausch + Lomb (BLCO.TO), opens new tab, will not be taken private at this time, the contact lens maker said on Thursday, sending its U.S.-listed shares down 7% to $16.50 in ...

(Reuters) -Bausch + Lomb will not be taken private at this time, the contact lens maker said on Thursday. In December, the company said it was exploring a potential sale and other options that ...

Richard Smith, head of professional affairs EMEA at Bausch + Lomb and chairman of the Association of Contact Lens ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX ... portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic ...

Bausch + Lomb (NYSE:BLCO – Free Report) had its price target cut by Bank of America from $18.00 to $17.00 in a research ...

and Daily SiHy lenses and Bausch + Lomb ULTRA ® in our contact lens business. Surgical segment revenue was $231 million for the fourth quarter of 2024, as compared to $204 million for the fourth ...

Bausch + Lomb is traded on both the New York Stock Exchange and Toronto Stock Exchange. This news release may contain forward-looking statements, which may generally be identified by the use of ...

We continue to introduce new products across businesses ... in the material side of the contact lenses in so many years. And in fact, Bausch + Lomb, one of its strengths is the capabilities ...

Bausch + Lomb (NYSE:BLCO – Get Free Report) had its price target decreased by Royal Bank of Canada from $22.00 to $18.00 in a research note issued to investors on Thursday, Ratings reports. The firm ...